Today's Date: March 28, 2024
Cardinal Tobin Blesses New Open-Air Mausoleum of the Holy Spirit Site   •   Fox Lake Grade School District 114 Selects Varsity Tutors for Schools to Provide Students with Additional Learning Resources   •   Stora Enso publishes Green and Sustainability-Linked Financing Report 2023   •   Lenzing strives to drive beneficial transformation across the value chain   •   Guo Guangchang: "Focus on building sustainable, predictable and enterprise with stable profit growth "   •   Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Forma   •   Lightshift Energy Raises $100 Million From Greenbacker Capital Management to Expand Utility Scale Battery Storage Across North A   •   Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows   •   Clean Energy Appoints Patrick J. Ford to Board of Directors   •   The Lenserf Group Launches Emotional Intelligence Academy for HBCU Interns   •   Apogee Enterprises Schedules Fourth Quarter Fiscal Year 2024 Earnings Release and Conference Call   •   Avnos and Deep Sky Forge Path to Gigaton-Scale Carbon Removal in Canada   •   3EO Health Announces the First Point of Care Molecular Test Under $15   •   PRIVATE SCHOOL VILLAGE (PSV) AWARDS INAUGURAL ELEMENTARY-SCHOOL SCHOLARSHIPS   •   The Home Depot Announces Agreement to Acquire SRS Distribution, a Leading Specialty Trade Distributor Across Multiple Verticals;   •   Government of Canada signs two bilateral agreements with Quebec to support initiatives to improve health care   •   SunCoke Energy, Inc. Issues 2023 Sustainability Report   •   SolarEdge Launches SolarEdge ONE Optimization Solution for Homeowners with a Dynamic Rate Plan in the Netherlands   •   Latest U.S. Soybean Field Trials by Texas Crop Science Deliver Average Yield Increase of More Than 20%   •   Chris Diehl Returns to 101 Mobility as Director of National Accounts
Bookmark and Share

TherapeuticsMD Provides Update on Third Quarter Progress

BOCA RATON, Fla. , September 25 /Businesswire/ - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Company’s ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen increases in orders to wholesalers, retail pharmacies and online distributors throughout the quarter that are greater than the patient demand numbers being reported by industry prescription tracking databases. In addition, weekly inventory on hand reported by wholesalers remains consistent over the quarter, indicating that inventory levels in the channel are not increasing. The Company believes that industry prescription tracking databases are not accurately reflecting the consistent underlying demand for ANNOVERA seen in orders to wholesalers, retail pharmacies and online distributors. The Company is working with industry prescription tracking databases to identify why this demand is not identified in their published numbers. The Company believes it is well positioned to meet or exceed third quarter 2020 total net revenue consensus, putting the Company on a strong trajectory for the fourth quarter.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements for TherapeuticsMD Inc.

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: https://ir.therapeuticsmd.com/press-releases.


STORY TAGS: Florida, Women, Consumer, Health, Pharmaceutical, Baby/Maternity, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News